Key Insights

Highlights

Success Rate

85% trial completion

Published Results

22 trials with published results (15%)

Research Maturity

61 completed trials (41% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

7.5%

11 terminated out of 147 trials

Success Rate

84.7%

-1.9% vs benchmark

Late-Stage Pipeline

2%

3 trials in Phase 3/4

Results Transparency

36%

22 of 61 completed with results

Key Signals

22 with results85% success11 terminated

Data Visualizations

Phase Distribution

94Total
Not Applicable (74)
Early P 1 (2)
P 1 (6)
P 2 (9)
P 3 (1)
P 4 (2)

Trial Status

Completed61
Recruiting27
Unknown20
Active Not Recruiting12
Terminated11
Enrolling By Invitation6

Trial Success Rate

84.7%

Benchmark: 86.6%

Based on 61 completed trials

Clinical Trials (147)

Showing 20 of 20 trials
NCT02994693Active Not RecruitingPrimary

Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy

NCT03459339Not ApplicableActive Not RecruitingPrimary

Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy

NCT07212491Enrolling By InvitationPrimary

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma

NCT05965999RecruitingPrimary

Lucid Registry Study

NCT07809620Recruiting

Preoperative Predictors of Symptom Improvement After Laparoscopic Fundoplication

NCT04295811Not ApplicableActive Not RecruitingPrimary

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC

NCT06687603Not ApplicableRecruitingPrimary

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

NCT03554356Not ApplicableActive Not RecruitingPrimary

Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)

NCT06732388Phase 2RecruitingPrimary

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

NCT02521285Phase 2Active Not RecruitingPrimary

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

NCT05753748Not ApplicableRecruiting

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

NCT00431756Active Not RecruitingPrimary

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

NCT03853772Enrolling By Invitation

The Johns Hopkins Heartburn Center Registry

NCT07788742Phase 4Not Yet RecruitingPrimary

Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)

NCT05463796Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT04939051Phase 2RecruitingPrimary

Obeticholic Acid for Prevention in Barrett's Esophagus

NCT06803927RecruitingPrimary

Non-Endoscopic Detection of Barrett's Esophagus Using Methylation Biomarkers on EndoSign® Cell Collection Device Samples

NCT05530343Not ApplicableRecruitingPrimary

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

NCT04867590Not ApplicableRecruitingPrimary

A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus

NCT07206589Not ApplicableNot Yet RecruitingPrimary

Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial

Scroll to load more

Research Network

Activity Timeline